EPIX

$0.00

(

+0.00%

) Quote details
Add to Watchlist Run Backtest
stock

ESSA Pharma Inc

NASDAQ | EPIX

0.20

USD

+$0.00

(

+0.00%

)

At Close (As of Sep 26, 2025)

$9.47M

Market Cap

-

P/E Ratio

-0.57

EPS

$6.77

52 Week High

$0.18

52 Week Low

HEALTHCARE

Sector

EPIX Chart

Recent Chart
Price Action

EPIX Technicals

Tags:

EPIX Earnings

Yearly Income Statement (As of Sep 30, 2024)

Field Value (USD)
Gross Profit -$91K
Total Revenue $0
Cost Of Revenue $91K
Costof Goods And Services Sold $91K
Operating Income -$34M
Selling General And Administrative $13M
Research And Development $21M
Operating Expenses $34M
Investment Income Net -
Net Interest Income $0
Interest Income -
Interest Expense $0
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $91K
Income Before Tax -$29M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$29M
Comprehensive Income Net Of Tax -
Ebit -$29M
Ebitda -$28M
Net Income -$29M

Revenue & Profitability

Earnings Performance

EPIX Financials

yearly Balance Sheet (As of Sep 30, 2024)

Field Value (USD)
Total Assets $128M
Total Current Assets $128M
Cash And Cash Equivalents At Carrying Value $104M
Cash And Short Term Investments $104M
Inventory -
Current Net Receivables $163K
Total Non Current Assets $552K
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments -
Short Term Investments $23M
Other Current Assets $636K
Other Non Current Assets -
Total Liabilities $3.5M
Total Current Liabilities $3.3M
Current Accounts Payable $2.4M
Deferred Revenue -
Current Debt -
Short Term Debt $248K
Total Non Current Liabilities $205K
Capital Lease Obligations $329K
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $329K
Other Current Liabilities $649K
Other Non Current Liabilities -
Total Shareholder Equity $125M
Treasury Stock -
Retained Earnings -$208M
Common Stock $280M
Common Stock Shares Outstanding $44M

yearly Cash Flow (As of Sep 30, 2024)

Field Value (USD)
Operating Cashflow -$23M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $91K
Capital Expenditures $0
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment $92M
Cashflow From Financing $926K
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$29M

yearly Income Statement (As of Sep 30, 2024)

Field Value (USD)
Gross Profit -$91K
Total Revenue $0
Cost Of Revenue $91K
Costof Goods And Services Sold $91K
Operating Income -$34M
Selling General And Administrative $13M
Research And Development $21M
Operating Expenses $34M
Investment Income Net -
Net Interest Income $0
Interest Income -
Interest Expense $0
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $91K
Income Before Tax -$29M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$29M
Comprehensive Income Net Of Tax -
Ebit -$29M
Ebitda -$28M
Net Income -$29M

Dividends

Field Value
Ex Dividend Date 2025-08-25
Declaration Date None
Record Date None
Payment Date None
Amount 1.691

EPIX News

EPIX Profile

ESSA Pharma Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

ESSA Pharma Inc. (EPIX) is a clinical-stage biopharmaceutical company headquartered in Vancouver, Canada, dedicated to the discovery and development of innovative therapies for prostate cancer. Leveraging its proprietary drug platform, ESSA aims to address significant unmet medical needs in oncology, particularly for advanced prostate cancer. With a robust pipeline and strategic partnerships, the company is well-positioned to advance its lead candidates through clinical trials and seek regulatory approval, ultimately enhancing treatment options for patients.

DVLT
+30.57%
$1.09
INTC
+4.44%
$35.50
GPUS
+19.56%
$0.45
CGBS
-39.47%
$0.03
DFLI
+38.45%
$0.52
NEHC
+33.33%
$1.84
NUAI
+33.33%
$1.84
SNAP
-0.72%
$8.27
CJET
+10.63%
$0.17
NVDA
+0.28%
$178.19
F
+3.35%
$12.01
DNN
-3.14%
$2.77
PSTV
+9.60%
$0.61
APLT
+121.34%
$1.24
TSLA
+4.01%
$440.40
RGTI
-2.86%
$31.18
BIAF
+55.13%
$5.29
YAAS
-8.19%
$0.09
PLUG
+0.42%
$2.37
CIFR
-1.62%
$11.47
NIO
-5.75%
$7.04
ADAP
+15.74%
$0.14
AAL
-0.70%
$11.31
WOK
-5.22%
$0.08
RIG
+0.94%
$3.19
IONZ
+5.83%
$4.34
TPIC
-45.91%
$0.12
AXDX
-61.36%
$0.03
MRM
+102.75%
$2.94
QBTS
+1.59%
$26.76
VALE
-1.74%
$10.70
IREN
-9.57%
$41.86
BLMZ
+12.51%
$0.20
BTG
+1.44%
$4.92
QUBT
-2.11%
$20.14
MARA
+0.37%
$16.13
KVUE
+1.54%
$16.42
RIOT
+5.67%
$17.69
KDLY
+7.69%
$1.26
RXRX
-5.12%
$4.63
AAPL
-0.54%
$255.46
ATCH
-4.22%
$0.79
PLTR
-0.86%
$177.57
SOUN
-2.50%
$15.94
BBD
+0.91%
$3.30
BITF
-5.22%
$2.54
TLRY
-3.36%
$1.14
WBD
-1.36%
$19.51
AMZN
+0.74%
$219.78
FCX
+1.14%
$35.74
BURU
-10.14%
$0.12
IXHL
-0.01%
$0.59
BMNR
+1.69%
$50.41
RMBL
+60.50%
$3.21
ETHD
-5.95%
$3.95
SHOT
+12.24%
$0.28
GRAB
-2.24%
$6.11
ADD
-25.47%
$0.05
CLSK
-5.32%
$13.68
RAYA
-3.15%
$0.04
RR
+2.68%
$4.20
RIVN
-0.95%
$15.59
ONDS
-1.16%
$7.66
SOFI
-0.49%
$27.98
BULL
+3.55%
$15.16
CVE
+0.39%
$17.77
SRM
+53.27%
$10.30
PFE
+0.67%
$23.76
ACHR
-0.53%
$9.27
IONQ
-3.09%
$67.28
BB
+6.34%
$4.94
JOBY
+1.63%
$16.12
NOK
-0.42%
$4.66
AMD
-1.12%
$159.46
CRWV
-4.98%
$120.34
CLF
+2.48%
$12.37
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
BTE
+2.64%
$2.52
QS
+1.28%
$12.66
WLGS
-5.57%
$0.04
HIMS
+6.39%
$58.38
ABEV
0.00%
$2.29
AQMS
+48.37%
$7.30
MRVL
-0.76%
$83.17
ETWO
0.00%
$3.30
ORCL
-2.70%
$283.45
HBAN
+0.57%
$17.42
AG
+4.02%
$12.14
HOOD
-0.70%
$121.78
NWTN
-15.63%
$2.04
AIIO
-15.63%
$2.04
SDM
-86.40%
$1.85
T
+0.03%
$28.31
OKLO
-7.21%
$110.53
ITUB
+0.55%
$7.24
MU
+0.28%
$157.27
PCG
+3.67%
$14.97
AFMD
-34.94%
$0.18
WULF
-1.27%
$10.83
DVLT
+30.57%
$1.09
INTC
+4.44%
$35.50
GPUS
+19.56%
$0.45
CGBS
-39.47%
$0.03
DFLI
+38.45%
$0.52
NEHC
+33.33%
$1.84
NUAI
+33.33%
$1.84
SNAP
-0.72%
$8.27
CJET
+10.63%
$0.17
NVDA
+0.28%
$178.19
F
+3.35%
$12.01
DNN
-3.14%
$2.77
PSTV
+9.60%
$0.61
APLT
+121.34%
$1.24
TSLA
+4.01%
$440.40
RGTI
-2.86%
$31.18
BIAF
+55.13%
$5.29
YAAS
-8.19%
$0.09
PLUG
+0.42%
$2.37
CIFR
-1.62%
$11.47
NIO
-5.75%
$7.04
ADAP
+15.74%
$0.14
AAL
-0.70%
$11.31
WOK
-5.22%
$0.08
RIG
+0.94%
$3.19
IONZ
+5.83%
$4.34
TPIC
-45.91%
$0.12
AXDX
-61.36%
$0.03
MRM
+102.75%
$2.94
QBTS
+1.59%
$26.76
VALE
-1.74%
$10.70
IREN
-9.57%
$41.86
BLMZ
+12.51%
$0.20
BTG
+1.44%
$4.92
QUBT
-2.11%
$20.14
MARA
+0.37%
$16.13
KVUE
+1.54%
$16.42
RIOT
+5.67%
$17.69
KDLY
+7.69%
$1.26
RXRX
-5.12%
$4.63
AAPL
-0.54%
$255.46
ATCH
-4.22%
$0.79
PLTR
-0.86%
$177.57
SOUN
-2.50%
$15.94
BBD
+0.91%
$3.30
BITF
-5.22%
$2.54
TLRY
-3.36%
$1.14
WBD
-1.36%
$19.51
AMZN
+0.74%
$219.78
FCX
+1.14%
$35.74
BURU
-10.14%
$0.12
IXHL
-0.01%
$0.59
BMNR
+1.69%
$50.41
RMBL
+60.50%
$3.21
ETHD
-5.95%
$3.95
SHOT
+12.24%
$0.28
GRAB
-2.24%
$6.11
ADD
-25.47%
$0.05
CLSK
-5.32%
$13.68
RAYA
-3.15%
$0.04
RR
+2.68%
$4.20
RIVN
-0.95%
$15.59
ONDS
-1.16%
$7.66
SOFI
-0.49%
$27.98
BULL
+3.55%
$15.16
CVE
+0.39%
$17.77
SRM
+53.27%
$10.30
PFE
+0.67%
$23.76
ACHR
-0.53%
$9.27
IONQ
-3.09%
$67.28
BB
+6.34%
$4.94
JOBY
+1.63%
$16.12
NOK
-0.42%
$4.66
AMD
-1.12%
$159.46
CRWV
-4.98%
$120.34
CLF
+2.48%
$12.37
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
BTE
+2.64%
$2.52
QS
+1.28%
$12.66
WLGS
-5.57%
$0.04
HIMS
+6.39%
$58.38
ABEV
0.00%
$2.29
AQMS
+48.37%
$7.30
MRVL
-0.76%
$83.17
ETWO
0.00%
$3.30
ORCL
-2.70%
$283.45
HBAN
+0.57%
$17.42
AG
+4.02%
$12.14
HOOD
-0.70%
$121.78
NWTN
-15.63%
$2.04
AIIO
-15.63%
$2.04
SDM
-86.40%
$1.85
T
+0.03%
$28.31
OKLO
-7.21%
$110.53
ITUB
+0.55%
$7.24
MU
+0.28%
$157.27
PCG
+3.67%
$14.97
AFMD
-34.94%
$0.18
WULF
-1.27%
$10.83
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.